Regulators in Japan have approved the use of an anticlotting drug developed by Bristol-Myers and Pfizer, the companies said Wednesday.
Eliquis can be used as a treatment for a type of irregular heartbeat called atrial fibrillation in patients who at risk for strokes or dangerous clots called systemic embolisms after getting the nod from the Japanese Ministry of Health, Labor and Welfare.
Bristol-Myers Squibb Co. and Pfizer Inc. announced last month that European regulators had approved the use of Eliquis. Canada has approved the drug as well.
The U.S. Food and Drug Administration is scheduled to make a decision by March 17.